- Klíčová slova
- centrové léky,
- MeSH
- biologická terapie * ekonomika klasifikace normy MeSH
- financování zdravotní péče * MeSH
- léčivé přípravky ekonomika klasifikace normy MeSH
- lékové předpisy ekonomika normy MeSH
- lidé MeSH
- omalizumab ekonomika terapeutické užití MeSH
- rozpočty klasifikace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
- Geografické názvy
- Česká republika MeSH
Introduction: Although there is a significant utilization gap of biologic medicines in the EU, many studies estimate equity in patient access to biopharmaceuticals only based on their availability on the national list of reimbursed medicines. Hidden access barriers may facilitate financial sustainability of pharmaceuticals in less affluent EU countries; however, they have rarely been documented in scientific publications. Our objective was to explore these access barriers for tumor necrosis factor (TNF) alpha inhibitors in rheumatoid arthritis (RA) in five Central and Eastern European countries. Methods: A detailed interview guide was developed based on multi-stakeholder workshops and a targeted literature review. In each participant country 3-3-3-3 interviews with payers, rheumatologists, patients/patient representatives, and industry representatives were conducted. Responses were aggregated at a country level and validated by primary investigators in each country. Results: Limited number of RA centers and consequently significant travelling time and cost for patients in distant geographical areas, uneven budget allocation among centers, limited capacity of nurses, narrowed patient population in national financial protocols compared to international clinical guidelines in initiating or continuing biologics, high administrative burden in prescribing biologics and limited health literacy of patients were the most relevant barriers to timely patient access in at least three participant countries. Conclusion: Assessing only the availability of TNF alpha inhibitors on the national list of reimbursed medicines provides limited information about real-world patient access to these medicines. Revealing hidden access barriers may contribute to initiate policy actions which could reduce inequity in patient access.
- Publikační typ
- časopisecké články MeSH
- Klíčová slova
- FIP,
- MeSH
- farmaceuti trendy MeSH
- farmaceutické služby MeSH
- farmacie * organizace a řízení trendy MeSH
- generika terapeutické užití MeSH
- kongresy jako téma MeSH
- léčivé přípravky zásobování a distribuce MeSH
- lékárny organizace a řízení trendy MeSH
- studium farmacie trendy MeSH
- Publikační typ
- zprávy MeSH
- Geografické názvy
- Korejská republika MeSH
- MeSH
- farmacie * MeSH
- kongresy jako téma MeSH
- vzdělávání pacientů jako téma MeSH
- Publikační typ
- zprávy MeSH
